Loading...

LivaNova PLC

LIVNNASDAQ
Healthcare
Medical - Devices
$56.35
$0.45(0.81%)

LivaNova PLC (LIVN) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for LivaNova PLC (LIVN), covering cash flow, earnings, and balance sheets.

Revenue Growth
8.66%
8.66%
Operating Income Growth
288.40%
288.40%
Net Income Growth
260.39%
260.39%
Operating Cash Flow Growth
144.33%
144.33%
Operating Margin
13.40%
13.40%
Gross Margin
69.07%
69.07%
Net Profit Margin
-16.14%
16.14%
ROE
-17.66%
17.66%
ROIC
10.45%
10.45%

LivaNova PLC (LIVN) Income Statement & Financial Overview

Analyze LivaNova PLC’s LIVN earnings with segmented quarterly and yearly financial statement figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$316.86M$321.80M$318.12M$318.57M
Cost of Revenue$96.08M$102.48M$92.86M$98.21M
Gross Profit$220.78M$219.30M$225.26M$220.37M
Gross Profit Ratio$0.70$0.68$0.71$0.69
R&D Expenses$37.88M$43.31M$48.80M$44.74M
SG&A Expenses$133.67M$135.62M$131.66M$129.12M
Operating Expenses$172.16M$182.33M$189.65M$173.85M
Total Costs & Expenses$268.24M$289.91M$282.50M$272.06M
Interest Income$6.44M$8.58M$7.14M$7.34M
Interest Expense$15.29M$15.77M$15.88M$15.53M
Depreciation & Amortization$0.00$12.58M$13.13M$12.29M
EBITDA-$285.69M$84.88M$73.45M$49.41M
EBITDA Ratio-$0.90$0.26$0.23$0.16
Operating Income$48.62M$37.02M$35.62M$46.51M
Operating Income Ratio$0.15$0.12$0.11$0.15
Other Income/Expenses (Net)-$364.26M$19.48M$8.82M-$18.58M
Income Before Tax-$315.65M$56.48M$44.44M$21.59M
Income Before Tax Ratio-$1.00$0.18$0.14$0.07
Income Tax Expense$11.66M$600000.00$11.53M$5.23M
Net Income-$327.32M$55.89M$32.95M$16.33M
Net Income Ratio-$1.03$0.17$0.10$0.05
EPS-$6.01$1.03$0.61$0.30
Diluted EPS-$6.01$1.02$0.60$0.30
Weighted Avg Shares Outstanding$54.42M$54.40M$54.35M$54.24M
Weighted Avg Shares Outstanding (Diluted)$54.42M$54.70M$54.59M$54.59M

Over the past four quarters, LivaNova PLC demonstrated steady revenue growth, increasing from $318.57M in Q2 2024 to $316.86M in Q1 2025. Operating income reached $48.62M in Q1 2025, maintaining a consistent 15% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$285.69M, reflecting operational efficiency. Net income dropped to -$327.32M, with EPS at -$6.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;